NEW YORK, Sept. 11 -- Affymetrix (Nasdaq: AFFX) of Santa Clara, Calif., said Monday it had licensed technology for low and medium density DNA arrays to reagent-provider Takara Shuzo of Kyoto, Japan.

Under the terms of the license, Takara has been granted a non-exclusive, worldwide, royalty-bearing license allowing them to manufacture, use and sell low and medium density pre-spotted arrays of up to 5,000 spots per slide.

Affymetrix has yet to license its high-density chip technology, preferring to keep that market for itself.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

The Atlantic reports that genetic counselors are coping with an influx of patients seeking advice on their direct-to-consumer genetic test results.

A small study finds differences between three genomic prostate cancer tests, Medscape reports.

In Nature this week: shared genetic architecture for asthma and allergic diseases, and more.

A survey of Canadians finds them to be divided on genetically modified food, the Ottawa Citizen reports.